Research analysts at Evercore ISI started coverage on shares of Akero Therapeutics (NASDAQ:AKRO) in a report issued on Monday, Marketbeat reports. The brokerage set an “outperform” rating and a $35.00 price target on the stock. Evercore ISI’s price target would suggest a potential upside of 70.48% from the stock’s current price.
Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. restated a “sell” rating and set a $18.00 price objective on shares of ABB in a research report on Monday. Roth Capital restated a “buy” rating on shares of Coeur Mining in a research report on Monday. Finally, Jefferies Financial Group lowered their price objective on shares of TherapeuticsMD from $4.00 to $3.00 in a research report on Monday.
Shares of Akero Therapeutics stock opened at $20.53 on Monday. Akero Therapeutics has a twelve month low of $16.06 and a twelve month high of $21.94.
About Akero Therapeutics
Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.
Recommended Story: Equity Income
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.